Infections associated with the use of biologic response modifiers in rheumatic diseases: A critical appraisal

Indian Journal of Rheumatology

Volumn 6, Issue 1 SUPPL., 2011, Pages 99-112

  Malaviya, An ^a   Haroon, Nigil ^b  

^a ISIC Superspeciality Hospital   (India)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL RESPONSE MODIFIER; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HERPES ZOSTER IMMUNOGLOBULIN; INFLIXIMAB; INFLUENZA VACCINE; LEFLUNOMIDE; METHOTREXATE; PNEUMOCOCCUS VACCINE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR INHIBITOR;

ADAPTIVE IMMUNITY; ANKYLOSING SPONDYLITIS; APPENDICITIS; ASEPTIC MENINGITIS; BACTERIAL ARTHRITIS; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BACTERIAL SKIN DISEASE; BELGIUM; BRONCHITIS; BRUCELLOSIS; CANDIDIASIS; CAUCASIAN; CELLULITIS; CERVICAL LYMPH NODE; CHICKENPOX; CHINA; COCCIDIOIDOMYCOSIS; COMMON COLD; COMORBIDITY; CROHN DISEASE; CYSTITIS; CYTOMEGALOVIRUS INFECTION; DENGUE; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG WITHDRAWAL; EAR INFECTION; ENDOCARDITIS; ENDOPHTHALMITIS; EPIGLOTTIS; ERYSIPELAS; EXTRAPULMONARY TUBERCULOSIS; FEVER; FOLLOW UP; FRANCE; GASTROENTERITIS; GASTROINTESTINAL INFECTION; GERMANY; HEALTH CARE PERSONNEL; HEMORRHAGIC COLITIS; HEPATITIS E; HERPES SIMPLEX ENCEPHALITIS; HERPES ZOSTER; HISTOPLASMOSIS; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INDIA; INDIAN; INFECTION; INFECTION CONTROL; INFECTION RISK; JUVENILE RHEUMATOID ARTHRITIS; KOREA; LEGIONELLA PNEUMOPHILA; LENGTH OF STAY; LISTERIA MONOCYTOGENES; LISTERIOSIS; LOWER RESPIRATORY TRACT INFECTION; LUNG ASPERGILLOSIS; LUNG INFECTION; LUNG TUBERCULOSIS; MASTOIDITIS; MENINGITIS; MORTALITY; MOUTH ULCER; MULTIPLE ORGAN FAILURE; MYCOBACTERIUM; MYCOSIS; NEUTROPENIA; NOCARDIOSIS; OPPORTUNISTIC INFECTION; PLEURA EFFUSION; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PYELONEPHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RHINOPHARYNGITIS; SALMONELLA; SCREENING; SEPSIS; SEPTICEMIA; SIDE EFFECT; SINUSITIS; SKIN INFECTION; SKIN ULCER; SOFT TISSUE INFECTION; SPAIN; SWEDEN; THORAX RADIOGRAPHY; THROAT IRRITATION; TONSILLITIS; TOOTH ABSCESS; TOXOPLASMOSIS; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; TUBERCULOUS LYMPHADENITIS; TUBERCULOUS PERITONITIS; TUBERCULOUS SPONDYLITIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINITIS; VIRUS INFECTION; VIRUS PNEUMONIA; WOUND INFECTION;

EID: 84992261196     PISSN: 09733698     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0973-3698(11)60040-X     Document Type: Review

References (96)

1. Doran M, Crowson CS, Pond GR, O'Fallon M, Gabriel SE. Frequency of infection in patients with RA compared with controls: a population-based study. Arthritis Rheum 2002; 46: 2287-93.
2. Doran M, Crowson CS, Pond GR, O'Fallon M, Gabriel SE. Predictors of infection in RA. Arthritis Rheum 2002; 46: 2294-300.
3. Fessler BJ. Infectious diseases in systemic lupus erythematosus: risk factors, management, and prophylaxis. Best Pract Res Clin Rheumatol 2002; 16: 281-91.
4. Furst DE. The risk of infections with biologic therapies for RA. Semin Arthritis Rheum 2010; 39: 327-46.
5. Ledwich LJ, Harrington TM, Ayoub WT, Sartorius JA, Newman ED. Improved influenza, and pneumococcal vaccination in rheumatology patients taking immunosuppressants using an electronic health record best practice alert. Arthritis Rheum (Arth Care & Res) 2009; 61: 1505-10.
6. McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L. Methotrexate, RA, and infection risk - what is the evidence? Rheumatology 2009; 48: 867-71.
7. Barshes NR, Goodpastor SE, Goss JA. Pharmacologic immunosuppression. Frontiers in Bioscience 2004; 9: 411-20. (Pubitemid 38925470)
8. eMedicine specialties > Pediatrics: Surgery > Transplantation immunosuppression. Prescilla RP, MD, Instructor in Anesthesia, Harvard Medical School; Assistant in Perioperative Anesthesia, Children's Hospital Boston, Updated: May 14, 2009.
9. The biologic revolution in RA: how TNF antagonists have optimized RA treatment and outcomes [http://cme.medscape.com/viewarticle/464118].
10. Weisman MH. Progress toward the cure of RA? The Best study. Arthritis Rheum 2005; 52: 3326-32. (Pubitemid 41612198)
11. Ma MHY, Scott IC, Kingsley GH, Scott DL. Remission in early RA. J Rheumatol 2010; 37: 1444-53.
12. Sokka T, Mäkinen H. Remission makes its way to rheumatology. Arth Res and Ther 2010, On-line first 12: 129doi:10.1186/ar3059.
13. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of RA. Anti-tumor necrosis factor trial in RA with concomitant therapy study group. New Eng J Med 2000; 343: 1594-602.
14. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with RA treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051-65. (Pubitemid 38480815)
15. St. Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early RA: a randomized, controlled trial. Arthritis Rheum 2004; 50: 3432-43. (Pubitemid 39488667)
16. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008; 35: 869-76. (Pubitemid 351747130)
17. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, et al. Persistent clinical efficacy and safety of anti-tumor necrosis factor alpha therapy with infliximab in patients with AS over 5 years: evidence for different types of response. Ann Rheum Dis 2008; 67: 340-5. (Pubitemid 351281268)
18. Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, et al. Efficacy and safety of infliximab in patients with AS over a two-year period. Arthritis Rheum 2008; 59: 1270-8.
19. Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile RA: findings from an open-label treatment extension. Ann Rheum Dis 2010; 69: 718-22.
20. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. ETA versus methotrexate in patients with early RA: two-year radiographic and clinical outcomes. Arthritis Rheum 2002; 46: 1443-50. (Pubitemid 34620189)
21. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of ETA and methotrexate, alone and combined, in the treatment of RA: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54: 1063-74. (Pubitemid 43672919)
22. van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination ETA and methotrexate versus ETA alone in patients with RA with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006; 65: 1478-83. (Pubitemid 44629126)
23. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and ETA in active, early, moderate to severe RA (COMET): a randomized, double-blind, parallel treatment trial. Lancet 2008; 372: 375-82.
24. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination ETA and sulfasalazine versus ETA alone in patients with RA: a double-blind randomized 2-year study. Ann Rheum Dis 2009; 68: 1146-52.
25. Spadaro A, Ceccarelli F, Scrivo R, Valesini G. Life-table analysis of ETA with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis 2008; 67: 1650-1.
26. Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, et al. ETA added to background methotrexate therapy in patients with RA: continued observations. Arthritis Rheum 2003; 48: 1493-9. (Pubitemid 36682355)
27. Martin-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BA, Vlahos B, Pedersen R, et al. Sustained efficacy and safety, including patient-reported outcomes, with ETA treatment over 5 years in patients with AS. Clin Exp Rheumatol 2010; 28: 238-45.
28. Davis JC Jr, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, et al. Efficacy and safety of up to 192 weeks of ETA therapy in patients with AS. Ann Rheum Dis 2008; 67: 346-52. (Pubitemid 351281269)
29. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous ETA therapy in patients with juvenile RA. Arthritis Rheum 2008; 58: 1496-504. (Pubitemid 351705939)
30. Lovell DJ, Reiff A, Jones OY, Schneider R, Nocton J, Stein LD, et al. Long-term safety and efficacy of ETA in children with polyarticular-course juvenile RA. Arthritis Rheum 2006; 54: 1987-94. (Pubitemid 43877949)
31. Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of ETA treatment in elderly subjects with RA. J Rheumatol 2006; 33: 234-43. (Pubitemid 43209297)
32. Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO III, Li J, Louie J, et al. Efficacy and safety of ETA 50 mg twice a week in patients with RA who had a suboptimal response to ETA 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008; 58: 1921-30. (Pubitemid 351988083)
33. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of SI in patients with RA especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) Advance Access published July 31, 2010; doi:10.1093/rheumatology/keq242.
34. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in RA patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76. (Pubitemid 44204996)
35. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-tumor necrosis factor alpha therapy in patients with RA: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56: 2896-904. (Pubitemid 47502735)
36. Listing J, Strangfeld A, Kary S, Rau R, von HU, Stoyanova-Scholz M, et al. Infections in patients with RA treated with biologic agents. Arthritis Rheum 2005; 52: 3403-12. (Pubitemid 41612206)
37. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Time-dependent increase in risk of hospitalization with infection among Swedish RA patients treated with TNF-antagonists. Ann Rheum Dis 2007; 66: 1339-44. (Pubitemid 47492478)
38. Tubach F, Ravaud P, Salmon-Céron D, Petitpain N, Brocq O, Grados F, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-α antagonists. Clin Infect Dis 2006; 43: e95-100.
39. Bassetti S, Wasmer S, Hasler P, Vogt T, Nogarth D, Frei R, et al. Staphylococcus aureus in patients with RA under conventional and anti-tumor necrosis factor-alpha treatment. J Rheumatol 2005; 32: 2125-9. (Pubitemid 41587855)
40. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in RA and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85. (Pubitemid 43736578)
41. Cairns AP, Taggart AJ. Anti-tumor necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J 2002; 71: 101-5. (Pubitemid 36002270)
42. Maillard H, Ornetti P, Grimault L, Ramon JF, Ducamp SM, Saidani T, et al. Severe pyogenic infections in patients taking infliximab: a regional cohort study. Jt Bone Spine 2005; 72: 330-4. (Pubitemid 40994981)
43. Hansen KE, Cush J, Singhal A, Cooley DA, Cohen S, Patel SR, et al. The safety and efficacy of leflunomide in combination with infliximab in RA. Arthritis Rheum 2004; 51: 228-32. (Pubitemid 38468706)
44. Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, van den Bosch F, et al. Four-year follow-up of infliximab therapy in RA patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 2006; 8: R112.
45. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with RA under anti-TNF-α therapy. Rheumatology (Oxford) 2003; 42: 617-21. (Pubitemid 37220869)
46. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56: 1125-33. (Pubitemid 46608637)
47. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, et al. On behalf of the Standards, Audit and Guidelines Working Group of BSR Clinical Affairs Committee and BHPR. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford) 2010; 49: 2217-9. Epub ahead of print.
48. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
49. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806. (Pubitemid 44497758)
50. Meijer JM, Pijpe J, Vissink A, Kallenberg CG, Bootsma H. Treatment of primary Sjögren's syndrome with rituximab: extended follow-up, safety, and efficacy of retreatment. Ann Rheum Dis 2009; 68: 284-5.
51. Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010; 69(Suppl 1): i2-29.
52. Lutt JR, Pisculli ML, Weinblatt ME, Deodhar A, Winthrop KL. Severe non-tuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. The Journal of Rheumatology 2008; 35: 1683-5.
53. Genovese MC, Breedveld FC, Emery P, Cohen S, Keystone E, Matteson EL, et al. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009; 68: 1894-7.
54. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96.
55. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying anti-rheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58: 2968-80.
56. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 2008; 371: 987-97. (Pubitemid 351392039)
57. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biological: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-23.
58. Nishimoto N, Ito K, Takagi N. Safety, and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Modern rheumatology/the Japan Rheumatism Association 2010; 20: 222-32.
59. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Modern rheumatology/the Japan Rheumatism Association 2009; 19: 12-9.
60. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumor necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009; 68: 1708-14.
61. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy. Ann Rheum Dis 2008; 67: 547-54. (Pubitemid 351498439)
62. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs. placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67: 1096-103.
63. Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2010; 37: 234-45.
64. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010; 62: 1792-802.
65. Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety, and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-9.
66. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45. (Pubitemid 36091645)
67. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 2006; 65: 753-9. (Pubitemid 43799174)
68. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26-37. (Pubitemid 43122183)
69. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508-16. (Pubitemid 38530193)
70. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11. (Pubitemid 38608061)
71. Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008; 59: 1467-74.
72. Miyasaka N, CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Modern rheumatology/the Japan Rheumatism Association 2008; 18: 252-62.
73. van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatology 2008; 27: 1021-8.
74. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
75. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60: 1884-94.
76. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737-44.
77. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008; 59: 800-6.
78. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter activesurveillance report. Arthritis Rheum 2003; 48: 2122-7. (Pubitemid 36959191)
79. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007; 34: 706-11.
80. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-9. (Pubitemid 38198820)
81. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk, and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005; 52: 1986-92. (Pubitemid 40994319)
82. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-86.
83. Narayanan K, Anand KP. Two year follow up of IFX therapy in inflammatory arthritis. J Ind Rheumatol Assoc 2005; 13 (Suppl 1): 7-8.
84. Grover R, Kapoor S, Marwaha V, Malaviya A, Gupta R, Kumar A. Clinical experience with infiximab in spondyloarthropathy: an open label study on fourteen patients. J Indian Rheumatol Assoc 2005; 13: 78-82.
85. Shalini S, Singh VK, Chaturvedi V. Strategy to prevent tuberculosis during anti-TNF therapy in juvenile anklosing spondylitis with low dose IFX without loading schedule: a one year open label study of toxicity and efficacy in 15 patients. J Indian Rheumatol Assoc 2005; 13(Suppl): 10-5.
86. Misra R, Amin S, Joshi VR, Rao URK, Aggarwal A, Patil S, Shovani V. Open-label evaluation of the efficacy and safety of ETA in RA. J Indian Rheumatol Assoc 2005; 13: 131-4.
87. Ghosh A, Kole A, Devi GI, Sarkar D, Haldar S, Dhar S. Treatment of AS with special reference to biologics: single center study. J Indian Rheumatol Assoc 2004; 12: 54-7.
88. Kumar A. Experience with anti-tumor necrosis factor-α therapy in India. APLAR J Rheumatol 2006; 9: 136-41. (Pubitemid 44057328)
89. Tandon VR, Mahajan A, Khajuria V, Kapoor V. Biologics, and challenges ahead for the physician. JIACM 2006; 7: 334-43.
90. Narayanan K, Bhakuni DS, Garg OP. Experience with rituximab in RA. Ind J Rheumatol 2009; 4: 136-7.
91. Narayanan K, Anand KP. Long-term follow-up of infliximab therapy in inflammatory arthritis. Ind J Rheumatol 2007; 2: 8-10. (Pubitemid 351266264)
92. Patil SP, Rambhad GS, Indian ETA Collaborative group. A post-marketing surveillance study to assess the safety of ETA (Enbrel) in adults with active rheumatoid arthritis (RA) and children with juvenile RA (JRA). Ind Med Gaztt 2007; 3XLI,11: 441-51.
93. Malaviya AN, Kapoor S, Garg S, Rawat R, Shankar S, Nagpal S, et al. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India - an audit report. J Rheumatol 2009; 36: 1414-20.
94. Malaviya AN, Kapoor S, Garg S, Rawat R. Recommended screening strategy for preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India - follow-up report. J Rheumatol 2010; 37: 209.
95. Fouque-Aubert A, Jette-Paulin L, Combescure C, Basch A, Tebib J, Gossec L. SI in patients with AS with and without TNF blockers: a systematic review and meta-analysis of randomized placebo-controlled trials. Ann Rheum Dis 2010; 69: 1756-61.
96. Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with RA treated with ADA, ETA, or IFX: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.